Do You Qualify for GLP-1 Medication? BMI, Insurance, and Eligibility Explained

Before you start comparing providers and pricing, there is a more fundamental question to answer: do you medically qualify for a GLP-1 weight loss medication in the first place? And if you do, will your insurance cover it?

These are not the same question. You can meet the clinical criteria for Wegovy or Zepbound and still face significant insurance hurdles. You can fail the standard eligibility threshold and still find a provider willing to evaluate your individual case. And you can be in a gray zone where the answer depends entirely on which platform you approach.

This guide covers the clinical criteria first, then the insurance layer, then what to do in specific edge cases.

The Clinical Eligibility Criteria

FDA approval for GLP-1 weight loss medications — Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), and Foundayo (orforglipron) — is based on the same two-threshold BMI framework.

Threshold 1: BMI of 30 or higher

A BMI of 30 or higher — classified as obesity — qualifies you for GLP-1 weight loss treatment without any additional health conditions required. This is the straightforward path.

What BMI 30 looks like by height:

BMI is calculated from height and weight alone. It does not account for muscle mass, age, ethnicity, or body composition. A muscular person with low body fat can have a BMI of 30 and not carry excess fat; a sedentary person with high body fat can have a BMI of 27 and carry substantial metabolic risk. BMI is an imperfect but administratively practical screening tool — providers and insurers use it because it is universal and easily documented.

Threshold 2: BMI of 27 or higher plus a qualifying condition

If your BMI falls in the 27–29.9 range (overweight), you can still qualify with documentation of at least one weight-related health condition. The FDA-recognized qualifying conditions for Wegovy and Zepbound include:

Type 2 diabetes — the most commonly documented qualifying condition; also the one most likely to support insurance coverage for both Wegovy and the diabetes-indicated Mounjaro/Ozempic.

Prediabetes — A1C of 5.7–6.4% or fasting glucose of 100–125 mg/dL. Many providers accept prediabetes as a qualifying comorbidity; insurance coverage on this basis is less consistent.

Hypertension — diagnosed and documented high blood pressure, whether treated or untreated. Standard definition: systolic ≥ 130 mmHg or diastolic ≥ 80 mmHg.

Dyslipidemia — high cholesterol or triglycerides. LDL ≥ 130 mg/dL, triglycerides ≥ 150 mg/dL, or current lipid-lowering medication.

Obstructive sleep apnea — diagnosed by polysomnography or home sleep test, whether or not currently treated with CPAP. Particularly relevant for Zepbound, which has a dedicated FDA-approved OSA indication.

Cardiovascular disease — established history of heart attack, stroke, coronary artery disease, or peripheral arterial disease. Also opens the cardiovascular risk reduction indication for Wegovy (approved March 2024) — important for insurance purposes with patients who have Medicare.

Non-alcoholic fatty liver disease (NAFLD/MASH) — increasingly recognized as a qualifying comorbidity, though not uniformly accepted by insurers.

The "at least one" rule matters. You do not need multiple qualifying conditions. A BMI of 28 with well-controlled hypertension on a single medication qualifies just as well as a BMI of 28 with hypertension, prediabetes, and high cholesterol. The threshold is met with one.

Absolute Disqualifying Conditions

Certain conditions rule out GLP-1 weight loss medications entirely, regardless of BMI or insurance. These are the automatic disqualifiers that will prevent a prescription from any legitimate provider:

Personal or family history of medullary thyroid carcinoma (MTC)

All FDA-approved GLP-1 medications carry a boxed warning about a theoretical risk of thyroid C-cell tumors, based on rodent studies. This risk has not been confirmed in humans, but the warning is precautionary and absolute. If you or a first-degree relative has a history of MTC, GLP-1 medications are contraindicated.

Multiple endocrine neoplasia type 2 (MEN 2)

MEN 2 is a rare genetic syndrome associated with elevated MTC risk. It disqualifies you from GLP-1 use for the same reason as the MTC history above.

Pregnancy or plans to become pregnant

GLP-1 medications are not approved for use during pregnancy. Most providers require confirmation that you are not pregnant and use of reliable contraception. The medications should be discontinued at least two months before attempting conception based on current guidance.

Severe hypersensitivity to the medication

Prior anaphylaxis or serious allergic reaction to the specific active ingredient disqualifies use of that medication. Patients who react to semaglutide may not react to tirzepatide or orforglipron — the molecules are different.

Relative Contraindications: Case-by-Case Assessment

These conditions do not automatically disqualify you but require careful clinical evaluation. Different providers handle them differently, and they may delay or complicate your prescription:

History of pancreatitis — GLP-1 medications are associated with a small increase in pancreatitis risk. Patients with a single prior episode of pancreatitis (fully resolved, with the underlying cause addressed) are evaluated individually. Patients with chronic pancreatitis or recurrent pancreatitis are generally not candidates.

Severe kidney disease — GLP-1 medications are largely safe in kidney disease, but very severe impairment (eGFR < 15 or on dialysis) warrants specialist input before prescribing.

Severe liver disease — significant hepatic impairment affects drug metabolism and requires evaluation.

History of eating disorders — clinical guidelines suggest careful assessment before prescribing GLP-1 medications to patients with a history of anorexia nervosa, bulimia nervosa, or binge eating disorder. The appetite-suppressing effects can complicate eating disorder recovery for some patients, while others find them therapeutic. Reputable providers will screen and discuss this.

Diabetic retinopathy — rapid glycemic improvement from tirzepatide or semaglutide in type 2 diabetes patients has been associated with worsening of pre-existing diabetic retinopathy in some cases. Ophthalmology follow-up is recommended for patients with established retinopathy.

Certain psychiatric medications — some antipsychotics and mood stabilizers affect weight through mechanisms that interact with GLP-1 medication. Your prescribing provider needs your full current medication list.

Age Eligibility

Adults (18+): All FDA-approved GLP-1 weight loss medications are approved for adults. All major telehealth GLP-1 platforms require patients to be 18 or older for enrollment.

Adolescents (12–17): Wegovy (injectable semaglutide) received FDA approval for adolescents aged 12 and older with obesity in 2022. However, telehealth platforms generally do not prescribe GLP-1s to patients under 18 — pediatric GLP-1 prescribing is handled by specialist pediatric obesity medicine programs, often associated with academic medical centers.

Adults over 65 / Medicare patients: Most telehealth platforms do not accept Medicare and therefore effectively limit access for patients over 65. LifeMD is the primary exception, accepting Medicare in many states. Clinical eligibility for older adults follows the same BMI thresholds as the general adult population.

Insurance Eligibility: A Separate and More Complex Question

Meeting the clinical eligibility criteria gets you a prescription. Insurance coverage is an entirely separate determination made by your insurer, not your prescribing clinician.

How common is coverage?

Approximately 25–30% of commercial insurance plans currently cover GLP-1 medications for weight loss. Coverage rates have been volatile — many employers added GLP-1 coverage in 2022–2024, and a significant number removed or restricted it in 2025–2026 as costs increased. The landscape changes frequently.

Medicare Part D does not broadly cover GLP-1s for weight loss alone, but covers Wegovy for patients with established cardiovascular disease (cardiovascular risk reduction indication, approved 2024) and Zepbound for moderate-to-severe obstructive sleep apnea (OSA indication, approved 2024). A Medicare GLP-1 Payment Demonstration for broader access is beginning in July 2026.

What insurers require for prior authorization

Even when a plan covers GLP-1 medications, prior authorization is almost always required. The prior auth process involves your provider submitting clinical documentation to demonstrate that you meet the plan's coverage criteria. Common requirements include:

BMI documentation — a recent measurement in a clinical record, not just self-reported. Telehealth providers who do not require any clinical verification create prior auth challenges later.

Qualifying comorbidity documentation — if your BMI is 27–29.9, your qualifying condition must be documented in a medical record, ideally with a diagnosis code and treatment history.

Step therapy — many plans require documentation that you have tried and failed a prior weight loss intervention before approving GLP-1 coverage. Common step therapy requirements include:

• Participation in a structured weight loss program (diet and exercise counseling) for a specified period
• Trial of an older weight loss medication (phentermine, orlistat, naltrexone/bupropion) in some plans
• Documentation of prior attempts at lifestyle modification

Step therapy requirements vary significantly by insurer and plan. Some require only documentation of lifestyle counseling; others require a specific period of documented attempt before approving the more expensive GLP-1.

Lab work — A1C, lipid panel, and basic metabolic panel are commonly required to document the clinical picture before approval.

How to check your coverage before enrolling in any platform

The most important step before choosing a telehealth platform is checking your insurance benefits. Several ways to do this:

1. Your insurer's member portal: Log in and search your plan's formulary for "semaglutide," "tirzepatide," "Wegovy," or "Zepbound." If the medication appears — even at a high tier — prior authorization is likely possible. If weight loss medications are explicitly listed as excluded, coverage is not available under that plan.

2. Found Health's free insurance check: Before you commit to any platform, Found Health offers a free insurance coverage check that contacts your insurer and returns an estimated copay. Use it even if you do not plan to enroll with Found.

3. Your HR department: If your insurance is through an employer, your HR or benefits team can tell you definitively whether GLP-1 weight loss medications are covered. This is faster than navigating insurer portals.

4. The platform you choose: Ro, WeightWatchers Clinic, Calibrate, Mochi Health, and others verify insurance benefits as part of their enrollment process. Some (like Ro) check before you pay anything; others check during enrollment.

Edge Cases: What to Do When You Are Borderline

"My BMI is 26–27 with health conditions"

Strictly speaking, the FDA threshold for the overweight + comorbidity pathway is BMI 27 or higher — BMI 26 does not technically qualify even with qualifying conditions. Some providers will evaluate patients in the 26–27 range if the clinical picture is compelling (significant metabolic disease, cardiovascular risk, documented weight-related complications). Calibrate and Mochi Health, which approach prescribing through a more comprehensive metabolic health lens, may be more willing to evaluate borderline cases than platforms that apply BMI thresholds mechanically. The honest answer is: at BMI 26, you are outside the approved indication and should expect most providers to decline.

"My BMI is right at the threshold — what if I measure slightly differently?"

BMI calculations use height and weight. Self-reported height and weight are used by telehealth platforms for the initial intake — there is no height/weight verification at intake for most providers. Providers do have clinical and ethical obligations not to prescribe based on knowingly inaccurate information. If your BMI fluctuates around the threshold depending on time of day, recent meals, or clothing, it is reasonable to use your typical morning weight without heavy clothing.

"I had bariatric surgery and am regaining weight"

GLP-1 medications are increasingly used in post-bariatric patients experiencing weight regain — a clinically recognized problem that affects a meaningful proportion of bariatric surgery patients within 5–10 years of surgery. You qualify using the same BMI and comorbidity criteria as any other patient. Some providers have specific experience with post-bariatric GLP-1 use; Form Health and Calibrate are both designed for complex metabolic cases.

"My plan covers GLP-1s but only after step therapy I haven't done"

Step therapy requirements can be addressed proactively. Ask your provider to document your history of weight loss attempts, lifestyle modification, and any prior medication trials in your prior auth submission. If your plan requires a structured weight loss program, enrollment in one (even briefly) before or alongside the PA submission may satisfy the requirement. Providers with dedicated PA concierge teams — Ro, Calibrate, WeightWatchers Clinic, Mochi Health — have institutional experience navigating step therapy requirements and achieving approvals.

"I was denied — what are my options?"

A denial is not final. Options include:

Peer-to-peer review: Your prescribing clinician requests a direct call with the insurer's medical reviewer to argue your case. Platforms with dedicated PA teams manage this process. Approval rates after peer-to-peer review are meaningfully higher than after initial denial for medically appropriate cases.

Formal appeal: A written appeal with additional documentation — expanded clinical notes, specialist support letters, published clinical guidelines — submitted to the insurer. You have the right to appeal any coverage denial.

External review: If the internal appeal is denied, most states allow an external independent review of coverage denials. Your state insurance commissioner's office can guide this process.

Self-pay: If insurance coverage cannot be obtained, the self-pay options are more affordable than most people assume. Wegovy pill through NovoCare starts at $149/month for starter doses. Zepbound through LillyDirect starts at $299/month. Platforms like GoodRx for Weight Loss provide brand-name access at $188–$238/month all-in.

The Eligibility Summary

The clinical eligibility question is usually simpler than people expect. The insurance question is where complexity lives — and where the right platform choice makes the biggest practical difference.

Our provider comparison identifies which platforms have the most effective prior authorization support, which accept Medicare, and which offer the best self-pay pricing for patients without coverage.